Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Pharma Bidders May Queue Up For A Slice Of Mankind Pharma And Scorching 25 Percent Growth

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's Mankind Pharma, which has seen exponential year-on-year growth of more than 25 percent, may be the latest attraction for large multinational pharma companies as speculation gathers steam that its deep roots in the largely untapped semi-urban and rural markets makes it an enviable takeover target

You may also be interested in...



Zooming From Zero To $400 Million: The Making of Mankind Pharma - India’s Fastest Growing Company

The head of India’s fastest-rising pharma company may be unconventional, but his willingness to take risks and do business differently has set the company on an upward trajectory.

Zooming From Zero To $400 Million: The Making of Mankind Pharma - India’s Fastest Growing Company

The head of India’s fastest-rising pharma company may be unconventional, but his willingness to take risks and do business differently has set the company on an upward trajectory.

India's Sales Rankings Shuffle As IMS Health Widens Audit To Hospitals And Doctors

MUMBAI - GlaxoSmithKline PLC gained the top sales slot in India with Augmentin (amoxicillin/clavulanate) as a result of data analysis firm IMS Health expanding its sales audit coverage in the country

Related Content

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel